SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    I Heidegger, H Klocker, E Steiner, V Skradski, M Ladurner, R Pichler, G Schäfer, W Horninger, J Bektic, [-2]proPSA is an early marker for prostate cancer aggressiveness, Prostate Cancer and Prostatic Disease, 2014, 17, 1, 70

    CrossRef

  2. 2
    P Massoner, T Thomm, B Mack, G Untergasser, A Martowicz, K Bobowski, H Klocker, O Gires, M Puhr, EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205, British Journal of Cancer, 2014, 111, 5, 955

    CrossRef

  3. 3
    Francesca Demichelis, Janet L. Stanford, Genetic predisposition to prostate cancer: Update and future perspectives, Urologic Oncology: Seminars and Original Investigations, 2014,

    CrossRef

  4. 4
    Willi Oberaigner, Barbara Sperner-Unterweger, Michael Fiegl, Sabine Geiger-Gritsch, Christian Haring, Increased suicide risk in cancer patients in Tyrol/Austria, General Hospital Psychiatry, 2014, 36, 5, 483

    CrossRef

  5. 5
    Willi Oberaigner, Sabine Geiger-Gritsch, Prediction of cancer incidence in Tyrol/Austria for year of diagnosis 2020, Wiener klinische Wochenschrift, 2014, 126, 19-20, 642

    CrossRef

  6. 6
    P. Stattin, S. Carlsson, B. Holmstrom, A. Vickers, J. Hugosson, H. Lilja, H. Jonsson, Prostate Cancer Mortality in Areas With High and Low Prostate Cancer Incidence, JNCI Journal of the National Cancer Institute, 2014, 106, 3, dju007

    CrossRef

  7. 7
    Brian T. Helfand, William J. Catalona, The Epidemiology and Clinical Implications of Genetic Variation in Prostate Cancer, Urologic Clinics of North America, 2014, 41, 2, 277

    CrossRef

  8. 8
    Anja Bruchmann, Corinna Roller, Tamara Vanessa Walther, Georg Schäfer, Sara Lehmusvaara, Tapio Visakorpi, Helmut Klocker, Andrew C B Cato, Danilo Maddalo, Bcl-2 associated athanogene 5 (Bag5) is overexpressed in prostate cancer and inhibits ER-stress induced apoptosis, BMC Cancer, 2013, 13, 1, 96

    CrossRef

  9. 9
    G. Christian Ramos, O. Juan Fullá, Detección precoz de cáncer de próstata, Revista Médica Clínica Las Condes, 2013, 24, 4, 654

    CrossRef

  10. 10
    G Schaefer, J-M Mosquera, R Ramoner, K Park, A Romanel, E Steiner, W Horninger, J Bektic, M Ladurner-Rennau, M A Rubin, F Demichelis, H Klocker, Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer, Prostate Cancer and Prostatic Disease, 2013,

    CrossRef

  11. 11
    Johannes Dominikus Pallua, Georg Schaefer, Christof Seifarth, Michael Becker, Stephan Meding, Sandra Rauser, Axel Walch, Michael Handler, Michael Netzer, Marina Popovscaia, Melanie Osl, Christian Baumgartner, Herbert Lindner, Leopold Kremser, Bettina Sarg, Georg Bartsch, Christian W. Huck, Günther K. Bonn, Helmut Klocker, MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer, Journal of Proteomics, 2013, 91, 500

    CrossRef

  12. 12
    Brian T. Helfand, Stacy Loeb, Qiaoyan Hu, Phillip R. Cooper, Kimberly A. Roehl, Barry B. McGuire, Nikola A. Baumann, William J. Catalona, Personalized Prostate Specific Antigen Testing Using Genetic Variants May Reduce Unnecessary Prostate Biopsies, The Journal of Urology, 2013, 189, 5, 1697

    CrossRef

  13. 13
    Yasuhide Kitagawa, Atsushi Mizokami, Mikio Namiki, Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening, Prostate International, 2013, 1, 2, 65

    CrossRef

  14. 14
    Girish Sardana, Eleftherios P Diamandis, Biomarkers for the diagnosis of new and recurrent prostate cancer, Biomarkers in Medicine, 2012, 6, 5, 587

    CrossRef

  15. 15
    Mattias Johansson, Benny Holmström, Sally R. Hinchliffe, Anders Bergh, Ulf-Håkan Stenman, Göran Hallmans, Fredrik Wiklund, Pär Stattin, Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: Longitudinal study, International Journal of Cancer, 2012, 130, 1
  16. 16
    Al B. Barqawi, Kevin J. Krughoff, Khadijah Eid, Current Challenges in Prostate Cancer Management and the Rationale behind Targeted Focal Therapy, Advances in Urology, 2012, 2012, 1

    CrossRef

  17. 17
    F. Demichelis, S. R. Setlur, S. Banerjee, D. Chakravarty, J. Y. H. Chen, C. X. Chen, J. Huang, H. Beltran, D. A. Oldridge, N. Kitabayashi, B. Stenzel, G. Schaefer, W. Horninger, J. Bektic, A. M. Chinnaiyan, S. Goldenberg, J. Siddiqui, M. M. Regan, M. Kearney, T. D. Soong, D. S. Rickman, O. Elemento, J. T. Wei, D. S. Scherr, M. A. Sanda, G. Bartsch, C. Lee, H. Klocker, M. A. Rubin, Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk, Proceedings of the National Academy of Sciences, 2012, 109, 17, 6686

    CrossRef

  18. 18
    S Miyamoto, K Ito, M Miyakubo, R Suzuki, T Yamamoto, K Suzuki, K Suzuki, H Yamanaka, Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy, Prostate Cancer and Prostatic Diseases, 2012, 15, 1, 75

    CrossRef

  19. 19
    G. Smailyte, B. Aleknaviciene, Incidence of prostate cancer in Lithuania after introduction of the Early Prostate Cancer Detection Programme, Public Health, 2012, 126, 12, 1075

    CrossRef

  20. 20
    L. Kong, G. Schafer, H. Bu, Y. Zhang, Y. Zhang, H. Klocker, Lamin A/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3K/AKT/PTEN pathway, Carcinogenesis, 2012, 33, 4, 751

    CrossRef

  21. 21
    Christopher E Barbieri, Francesca Demichelis, Mark A Rubin, Molecular genetics of prostate cancer: emerging appreciation of genetic complexity, Histopathology, 2012, 60, 1
  22. 22
    Julia Hoefer, Georg Schäfer, Helmut Klocker, Holger H.H. Erb, Ian G. Mills, Ludger Hengst, Martin Puhr, Zoran Culig, PIAS1 Is Increased in Human Prostate Cancer and Enhances Proliferation through Inhibition of p21, The American Journal of Pathology, 2012, 180, 5, 2097

    CrossRef

  23. You have free access to this content23
    Nicolaas Lumen, Valérie Fonteyne, Gert De Meerleert, Piet Ost, Geert Villeirs, Alexandre Mottrie, Pieter De Visschere, Bart De Troyer, Willem Oosterlinck, Population screening for prostate cancer: An overview of available studies and meta-analysis, International Journal of Urology, 2012, 19, 2
  24. 24
    Roman Ganzer, Andreas Brandtner, Wolf F. Wieland, Hans-Martin Fritsche, Prospective blinded comparison of real-time sonoelastography targeted versus randomised biopsy of the prostate in the primary and re-biopsy setting, World Journal of Urology, 2012, 30, 2, 219

    CrossRef

  25. 25
    Willi Oberaigner, Uwe Siebert, Wolfgang Horninger, Helmut Klocker, Jasmin Bektic, Georg Schäfer, Ferdinand Frauscher, Harald Schennach, Georg Bartsch, Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008, International Journal of Public Health, 2012, 57, 1, 57

    CrossRef

  26. 26
    Petra Massoner, Angelika Lueking, Heike Goehler, Annabel Höpfner, Axel Kowald, Karl G. Kugler, Peter Amersdorfer, Wolfgang Horninger, Georg Bartsch, Peter Schulz-Knappe, Helmut Klocker, Serum-autoantibodies for discovery of prostate cancer specific biomarkers, The Prostate, 2012, 72, 4
  27. You have free access to this content27
    Yasuhide Kitagawa, Atsushi Mizokami, Kazuyoshi Nakashima, Kiyoshi Koshida, Masayoshi Shimamura, Kimiomi Miyazaki, Nobu Koyama, Mikio Namiki, Clinical outcomes of prostate cancer patients detected by prostate-specific antigen-based population screening in Kanazawa City, Japan, International Journal of Urology, 2011, 18, 8
  28. 28
    Ronald Ennis, Alan Jotkowitz, Good Ethics Begins With Sound Medicine: Prostate Cancer Screening and Chemoprevention, The American Journal of Bioethics, 2011, 11, 12, 26

    CrossRef

  29. 29
    John M. Fitzpatrick, Joaquim Bellmunt, Robert Dreicer, Neil E. Fleshner, Christopher J. Logothetis, Judd W. Moul, Bertrand Tombal, Alexandre Zlotta, Maximizing outcomes in genitourinary cancers across the treatment continuum, BJU International, 2011, 107,
  30. 30
    Heather Payne, Philip Cornford, Prostate-specific antigen: An evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer, Urologic Oncology: Seminars and Original Investigations, 2011, 29, 6, 593

    CrossRef

  31. 31
    Richard M. Hoffman, Screening for Prostate Cancer, New England Journal of Medicine, 2011, 365, 21, 2013

    CrossRef

  32. 32
    Martin Kerick, Melanie Isau, Bernd Timmermann, Holger Sültmann, Ralf Herwig, Sylvia Krobitsch, Georg Schaefer, Irmgard Verdorfer, Georg Bartsch, Helmut Klocker, Hans Lehrach, Michal R Schweiger, Targeted high throughput sequencing in clinical cancer Settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity, BMC Medical Genomics, 2011, 4, 1, 68

    CrossRef

  33. 33
    Huajie Bu, Stefanie Bormann, Georg Schäfer, Wolfgang Horninger, Petra Massoner, Antje Neeb, Vinoth-Kumar Lakshmanan, Danilo Maddalo, Andrea Nestl, Holger Sültmann, Andrew C.B. Cato, Helmut Klocker, The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection, The Prostate, 2011, 71, 6
  34. 34
    General Practice, 2011,

    CrossRef

  35. 35
    Ingrid Metzler, Biomarkers and their consequences for the biomedical profession: a social science perspective, Personalized Medicine, 2010, 7, 4, 407

    CrossRef

  36. 36
    Kenya Yamaguchi, Chemoprevention of Prostate Cancer, Journal of Nihon University Medical Association, 2010, 69, 2, 75

    CrossRef

  37. 37
    Ramzi Rajab, Gabrielle Fisher, Michael W. Kattan, Christopher S. Foster, Tim Oliver, Henrik Møller, Victor Reuter, Peter Scardino, Jack Cuzick, Daniel M. Berney, Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort, Virchows Archiv, 2010, 457, 5, 547

    CrossRef

  38. 38
    Jonas Hugosson, Sigrid Carlsson, Gunnar Aus, Svante Bergdahl, Ali Khatami, Pär Lodding, Carl-Gustaf Pihl, Johan Stranne, Erik Holmberg, Hans Lilja, Mortality results from the Göteborg randomised population-based prostate-cancer screening trial, The Lancet Oncology, 2010, 11, 8, 725

    CrossRef

  39. 39
    Pim J. van Leeuwen, David Connolly, Anna Gavin, Monique J. Roobol, Amanda Black, Chris H. Bangma, Fritz H. Schröder, Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit, European Journal of Cancer, 2010, 46, 2, 377

    CrossRef

  40. 40
    Seth A. Strope, Gerald L. Andriole, Prostate cancer screening: current status and future perspectives, Nature Reviews Urology, 2010, 7, 9, 487

    CrossRef

  41. 41
    Flip H. Jansen, Ron H.N. van Schaik, Joep Kurstjens, Wolfgang Horninger, Helmut Klocker, Jasmin Bektic, Mark F. Wildhagen, Monique J. Roobol, Chris H. Bangma, Georg Bartsch, Prostate-Specific Antigen (PSA) Isoform p2PSA in Combination with Total PSA and Free PSA Improves Diagnostic Accuracy in Prostate Cancer Detection, European Urology, 2010, 57, 6, 921

    CrossRef

  42. 42
    Stacy Loeb, William J Catalona, Prostate-specific antigen screening: pro, Current Opinion in Urology, 2010, 20, 3, 185

    CrossRef

  43. 43
    J.A. Gelpi-Méndez, E. Gómez-Fernández, J. Martín-Barallat, M.V. Cortés-Arcas, J.V. Monsonis-Artero, A. Calvo-Mora, Reference values of prostate specific antigen (PSA) in 63926 workers without prostatic symptoms who participated in prostate screening cancer developed by the Ibermutuamur Prevention Society in 2006, Actas Urológicas Españolas (English Edition), 2010, 34, 8, 669

    CrossRef

  44. 44
    Xiaoye Zhu, Monique J Roobol, Fritz H Schröder, Screening for prostate cancer: have we resolved the controversy?, Current Opinion in Supportive and Palliative Care, 2010, 4, 3, 121

    CrossRef

  45. 45
    Richard Olivier Fourcade, Ágnes Benedict, Libby K. Black, Michael E. Stokes, Antonio Alcaraz, Ramiro Castro, Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK, BJU International, 2010, 105, 1
  46. You have free access to this content46
    Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010, International Journal of Urology, 2010, 17, 10
  47. 47
    Tadashi Oeda, Norihiro Kusumi, Atsushi Takamoto, USEFULNESS OF SCREENING FOR PROSTATE CANCER WITH PROSTATE SPECIFIC ANTIGEN (PSA) IN THE MEDICAL CHECKUP ("HUMAN DOCK") AT ONOMICHI MUNICIPAL HOSPITAL: CLINICAL SIGNIFICANCE OF THE CASES DIAGNOSED AS PROSTATE CANCER, The Japanese Journal of Urology, 2010, 101, 1, 18

    CrossRef

  48. 48
    J.A. Gelpi-Méndez, E. Gómez-Fernández, J. Martín-Barallat, M.V. Cortés-Arcas, J.V. Monsonis-Artero, A. Calvo-Mora, Valores de referencia del antígeno prostático específico (PSA) en 63.926 trabajadores sin síntomas prostáticos que participaron en el cribado de cáncer de próstata desarrollado por la Sociedad de Prevención de Ibermutuamur durante el año 2006, Actas Urológicas Españolas, 2010, 34, 8, 669

    CrossRef

  49. 49
    Friedrich Aigner, Leo Pallwein, Daniel Junker, Georg Schäfer, Gregor Mikuz, Florian Pedross, Michael Josef Mitterberger, Werner Jaschke, Ethan J. Halpern, Ferdinand Frauscher, Value of Real-Time Elastography Targeted Biopsy for Prostate Cancer Detection in Men With Prostate Specific Antigen 1.25 ng/ml or Greater and 4.00 ng/ml or Less, The Journal of Urology, 2010, 184, 3, 913

    CrossRef

  50. 50
    Anton Ponholzer, Franz Stoiber, Wolfgang Loidl, Michael Rauchenwald, Paul Schramek, Stephan Madersbacher, Aktueller Einsatz von PSA, Wiener Medizinische Wochenschrift, 2009, 159, 21-22, 515

    CrossRef

  51. 51
    J E Elkahwaji, R J Hauke, C M Brawner, Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate, British Journal of Cancer, 2009, 101, 10, 1740

    CrossRef

  52. 52
    Yoshimi Tamura, Tomoko Koya, Takahiro Morita, Yutaka Kubota, Osamu Takahashi, Isao Fujiduka, Kazuto Ito, Kazuhiro Suzuki, CLINICAL RESEARCH OF PROSTATE CANCER DETECTED IN TONE CENTRAL HOSPITAL-COMPARISON OF SURVIVAL RATES BETWEEN PATIENTS DIAGNOSED WITH PROSTATE CANCER IN AND OUTSIDE SCREENING SYSTEM-, The Japanese Journal of Urology, 2009, 100, 4, 525

    CrossRef

  53. 53
    Kenneth J. Pienta, Critical Appraisal of Prostate-specific Antigen in Prostate Cancer Screening: 20 Years Later, Urology, 2009, 73, 5, S11

    CrossRef

  54. 54
    Badrinath R. Konety, Hrishikesh Raut, Brian J. Smith, Victoria J. Sharp, Richard D. Williams, Effect of Uniform Consensus Recommendations for PCa Screening in Older Population: Differential Effects and Perceptions of Healthcare Providers and Patients, Urology, 2009, 73, 3, 603

    CrossRef

  55. 55
    J. Jegu, B. Tretarre, P. Grosclaude, X. Rebillard, V. Bataille, B. Malavaud, F. Iborra, G. Salama, P. Rischmann, A. Villers, État des lieux et facteurs de participation à l’étude européenne ERSPC de dépistage randomisé du cancer de la prostate par dosage sérique de l’antigène prostatique spécifique : départements français du Tarn et de l’Hérault, Progrès en Urologie, 2009, 19, 7, 487

    CrossRef

  56. 56
    Don W.W. Newling, Issues with the Use of Prostate-Specific Antigen as a Surrogate End Point in Hormone-Resistant Prostate Cancer, European Urology Supplements, 2009, 8, 1, 13

    CrossRef

  57. 57
    C. S. Thaxton, R. Elghanian, A. D. Thomas, S. I. Stoeva, J.-S. Lee, N. D. Smith, A. J. Schaeffer, H. Klocker, W. Horninger, G. Bartsch, C. A. Mirkin, Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy, Proceedings of the National Academy of Sciences, 2009, 106, 44, 18437

    CrossRef

  58. 58
    Badrinath R. Konety, Panning for Prostate Gold: Urine Based Markers for Prostate Cancer, The Journal of Urology, 2009, 181, 1, 9

    CrossRef

  59. 59
    Stephan Madersbacher, Christian Vutuc, Prostatakarzinom-Screening: Sinn oder Unsinn?, Wiener klinische Wochenschrift, 2009, 121, 13-14, 428

    CrossRef

  60. 60
    Michael Marberger, Prostate Cancer 2008: Challenges in Diagnosis and Management, European Urology Supplements, 2009, 8, 3, 89

    CrossRef

  61. 61
    Hans Heinzer, Thomas Steuber, Prostate cancer in the elderly, Urologic Oncology: Seminars and Original Investigations, 2009, 27, 6, 668

    CrossRef

  62. You have free access to this content62
    Kazuto Ito, Prostate-specific antigen-based screening for prostate cancer: Evidence, controversies and future perspectives, International Journal of Urology, 2009, 16, 5
  63. 63
    Christian Vutuc, Thomas Waldhoer, Gerhard Lunglmayr, Wolfgang Hoeltl, Gerald Haidinger, PSA testing in Austria: induced morbidity and saved mortality, European Journal of Cancer Prevention, 2009, 18, 5, 377

    CrossRef

  64. 64
    JOHN M. FITZPATRICK, Epidemiological Studies from Europe, BJU International, 2008, 101, 11
  65. 65
    B. Arndt, M. Kwiatkowski, F. Recker, Stand der Prostatakarzinomvorsorge im Jahr 2008, Der Urologe, 2008, 47, 8, 969

    CrossRef